Morgan Stanley Bio Affinity Technologies, Inc. Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
A detailed history of Morgan Stanley transactions in Bio Affinity Technologies, Inc. stock. As of the latest transaction made, Morgan Stanley holds 4,961 shares of BIAF stock, worth $6,102. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,961
Previous 1,000
396.1%
Holding current value
$6,102
Previous $2,000
400.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding BIAF
# of Institutions
15Shares Held
468KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA261KShares$320,8680.0% of portfolio
-
Geode Capital Management, LLC Boston, MA87.2KShares$107,2320.0% of portfolio
-
Captrust Financial Advisors Raleigh, NC27.9KShares$34,2980.0% of portfolio
-
Sheaff Brock Investment Advisors, LLC20KShares$24,6000.0% of portfolio
-
State Street Corp Boston, MA17.6KShares$21,6480.0% of portfolio
About bioAffinity Technologies, Inc.
- Ticker BIAF
- Exchange
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 2,727,580
- Market Cap $3.35M
- Description
- bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is b...